Cyclic-di-GMP disodium 是一种STING激动剂，也是细菌第二信使，协调细菌生长和行为的不同方面，包括运动能力、毒力、生物膜的形成和细胞周期的进展。Cyclic-di-GMP disodium 具有抗癌细胞增殖活性，还可诱导CD4受体表达升高和细胞周期停滞。Cyclic-di-GMP disodium 可用于癌症的研究。
| 生物活性 | Cyclic-di-GMP disodium is aSTINGagonist and abacterialsecond messengerthat coordinates different aspects ofbacterialgrowth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevatedCD4receptorexpression and cell cycle arrest. Cyclic-di-GMP disodium can be used incancerresearch[1][2][3][4]. |
| IC50& Target | |
体外研究
(In Vitro) | Cyclic-di-GMP disodium (0.5-50 μM; 5 days) inhibits proliferation of human colon cancer cells[1].
Cyclic-di-GMP disodium (0.5-50 μM; 5 days) specifically elevates CD4 expression in Jurkat cells[2].
Cyclic-di-GMP disodium (0.5-50 μM; 5 days) induces cell cycle arrest at the S-phase in Jurkat cells[2].
Cell Proliferation Assay[1] | Cell Line: | H508 cells | | Concentration: | 0.5-50 μM | | Incubation Time: | 5 days | | Result: | Reduced basal H508 cell proliferation by approx 15%, even inhibited acetylcholine- and EGF-induced cell proliferation. |
Cell Viability Assay[2] | Cell Line: | Jurkat cells | | Concentration: | 50 μM | | Incubation Time: | 24 h | | Result: | Specifically induced of CD4 (no effect on the expression of CD8), with a 6.3-fold upregulation over control and in a dose-dependent manner. |
Cell Cycle Analysis[2] | Cell Line: | Jurkat cells | | Concentration: | 50 μM | | Incubation Time: | 24 h | | Result: | Increased the percentage of cells in S-phase by 79%, with almost complete disappearance of G2/M-phase cells which decreased by 93%. |
|
体内研究
(In Vivo) | Cyclic-di-GMP disodium (100 μg/per; i.v.; two sequential vaccinations 9 days apart) enhances TriVax-induced immune responses to melanoma in mice and further increased the anti-tumor effects of TriVax[3].
| Animal Model: | C57BL/6 (B6) mice (8- to 10-week-old)[3]. | | Dosage: | 100 μg/per | | Administration: | Intravenous injection; two sequential vaccinations 9 days apart; combine with TriVax. | | Result: | Significantly higher numbers of antigen-specific CD8 T cells when combined with TriVax. (TriVax consisted of a mixture of 120 μg Pam-hgp100, 100 μg hgp100 or 100 μg Ova, 50 or 25 μg anti-CD40 antibody, and 25 μg Poly-IC).
Enhanced the anti-tumor activity of TriVax. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | -80°C, protect from light, stored under nitrogen |
| 溶解性数据 | In Vitro: H2O : 160 mg/mL(217.87 mM;Need ultrasonic) 配制储备液 | 1 mM | 1.3617 mL | 6.8086 mL | 13.6171 mL | | 5 mM | 0.2723 mL | 1.3617 mL | 2.7234 mL | | 10 mM | 0.1362 mL | 0.6809 mL | 1.3617 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months (protect from light, stored under nitrogen)。-80℃ 储存时，请在 6 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 50 mg/mL (68.09 mM); Clear solution; Need ultrasonic
*以上所有助溶剂都可在本网站选购。 |
